|
?:authorAffiliation
|
-
[\'The Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.\', \'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.\', \'Nuffield Department of Medicine, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.\', \'Institute of Virology, Philipps University of Marburg, Marburg, Germany.\', \'NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, UK.\', \'School of Population Health Sciences, University of Bristol, Bristol, UK.\', \'National Infection Service, Public Health England, Salisbury, UK.\', \'Vaccine Institute, St George\'s University, London, UK.\', \'Department of Microbiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.\', \'NIHR Imperial Clinical Research Facility, Imperial College London, London, UK.\', \'Clinical Biomanufacturing Facility, University of Oxford, Oxford, UK.\', \'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. Electronic address: andrew.pollard@paediatrics.ox.ac.uk.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}